Cargando…

Immunomodulatory Drugs for the Treatment of B Cell Malignancies

Accumulating evidence suggests that the tumor microenvironment (TME) is involved in disease progression and drug resistance in B cell malignancies, by supporting tumor growth and facilitating the ability of malignant cells to avoid immune recognition. Immunomodulatory drugs (IMiDs) such as lenalidom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ioannou, Nikolaos, Jain, Khushi, Ramsay, Alan G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395307/ https://www.ncbi.nlm.nih.gov/pubmed/34445275 http://dx.doi.org/10.3390/ijms22168572

Ejemplares similares

Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy
por: Apollonio, Benedetta, et al.
Publicado: (2021)

Immunomodulatory and Antioxidant Drugs in Glaucoma Treatment
por: Buonfiglio, Francesco, et al.
Publicado: (2023)

Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment
por: Piccolomo, Antonio, et al.
Publicado: (2020)

The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy
por: Arruga, Francesca, et al.
Publicado: (2023)

Key regulators of sensitivity to immunomodulatory drugs in cancer treatment
por: Wang, Shichao, et al.
Publicado: (2021)

Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa—Possibilities and Limitations
por: Świerczewska, Zuzanna, et al.
Publicado: (2022)

Immunomodulatory aspects in the progression and treatment of oral malignancy
por: Kondoh, Nobuo, et al.
Publicado: (2019)

The role of B cells in heart failure and implications for future immunomodulatory treatment strategies
por: García‐Rivas, Gerardo, et al.
Publicado: (2020)

Novel immunomodulatory drugs and neo-substrates
por: Gao, Shaobing, et al.
Publicado: (2020)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Antiviral and Immunomodulatory Drugs
por: Sykes, Jane E., et al.
Publicado: (2014)

Immunomodulatory Drugs in Melanoma Brain Metastases
por: Fernandes, Gil Nuno Castro
Publicado: (2019)

Immunomodulatory drugs: Oral and systemic adverse effects
por: Bascones-Martinez, Antonio, et al.
Publicado: (2014)

Immunomodulatory Nanomedicine for the Treatment of Atherosclerosis
por: Peters, Linsey J. F., et al.
Publicado: (2021)

Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms
por: Guo, Hao, et al.
Publicado: (2022)

Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy
por: Matsushita, Maiko, et al.
Publicado: (2018)

Immunomodulatory Treatment Strategies Targeting B Cells for Heart Failure
por: Zhang, Xinxin, et al.
Publicado: (2022)

Immunomodulatory treatment of interstitial lung disease
por: van den Bosch, Laura, et al.
Publicado: (2022)

Immunomodulatory and immunosuppressive drug protocols in the treatment of canine primary immune thrombocytopenia, a scoping review
por: Kristiansen, Peter Spanner, et al.
Publicado: (2021)

Immunomodulatory drugs in pregnancy and lactation
por: Paizis, Kathy
Publicado: (2019)

Complement Activation in the Treatment of B-Cell Malignancies
por: Zent, Clive S., et al.
Publicado: (2020)

Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome
por: Arachchillage, Deepa J., et al.
Publicado: (2023)

Immunomodulatory Nanosystems
por: Feng, Xiangru, et al.
Publicado: (2019)

Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma
por: Charliński, Grzegorz, et al.
Publicado: (2021)

Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
por: Mohty, Razan, et al.
Publicado: (2022)

Editorial: Immunomodulatory Effects of Drugs for Treatment of Immune-Related Diseases
por: Maghazachi, Azzam A.
Publicado: (2017)

Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor
por: Ng, Dave Yong Xiang, et al.
Publicado: (2022)

Micro- and Nano-Based Transdermal Delivery Systems of Photosensitizing Drugs for the Treatment of Cutaneous Malignancies
por: Portugal, Isabella, et al.
Publicado: (2021)

Immunomodulatory Function of Myeloid-Derived Suppressor Cells during B Cell-Mediated Immune Responses
por: Özkan, Bilgenaz, et al.
Publicado: (2018)

Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas
por: Zhang, Qing, et al.
Publicado: (2020)

Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs
por: D'Souza, Criselle, et al.
Publicado: (2021)

Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications
por: Spanakis, Marios, et al.
Publicado: (2023)

Immunomodulatory Effect of Mesenchymal Stem Cells on B Cells
por: Franquesa, Marcella, et al.
Publicado: (2012)

Targeting CD22 for the Treatment of B-Cell Malignancies
por: Shah, Nikesh N, et al.
Publicado: (2021)

Immunomodulatory Therapies for the Treatment of Graft-versus-host Disease
por: Braun, Lukas M., et al.
Publicado: (2021)

Psoriatic arthritis: Pathogenesis and novel immunomodulatory approaches to treatment
por: Cassell, Sarah, et al.
Publicado: (2005)

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
por: Chanan-Khan, A A, et al.
Publicado: (2013)

Immunomodulatory Protein Hydrolysates and Their Application
por: Kiewiet, Mensiena B. G., et al.
Publicado: (2018)

Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
por: Hideshima, T, et al.
Publicado: (2015)

Repurposing Immunomodulatory Drugs to Combat Tuberculosis
por: Fatima, Samreen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ugn6220qo3i0mebc4mfrutt9da